2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Sunday, October 21, 2018

9:00AM-11:00AM: Abstract Number: 736

Herpes Zoster and Disseminated Zoster in Systemic Lupus Erythematosus and Lupus Nephritis: Incidence Rates in Real-World Claims Data

Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

9:00AM-11:00AM: Abstract Number: 769

Herpes Zoster in Systemic Lupus Erythematosus: Prevalence and Risk Factors

Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

9:00AM-11:00AM: Abstract Number: 135

High Dimensional Analysis By Mass Cytometry and RNA-Sequencing Reveals Altered Frequency and Exhausted Features of CD4 T and MAIT Cells in Systemic Sclerosis

T Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 148

High Level of CD38 Expression in SLE CD8 T Cells Dictates Decreased Cytotoxicity

T Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 669

High Prevalence of Axial Spondyloarthritis in Patients with Acute Anterior Uveitis and Chronic Back Pain – Preliminary Results of a Prospective Observational Study

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment

9:00AM-11:00AM: Abstract Number: 243

High Prevalence of Fibromyalgia Among Israel School Teachers

Fibromyalgia and Other Clinical Pain Syndromes Poster

9:00AM-11:00AM: Abstract Number: 712

Higher Prednisolone Dose during Treatment of Tuberculosis Correlates with Mortality during Tuberculosis Treatment in Systemic Lupus Erythematosus Patients: A Retrospective Cohort Study

Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

9:00AM-11:00AM: Abstract Number: 106

Highly Elevated Levels of Anti-Mitochondrial Antibodies in Systemic Lupus Erythematosus and Rheumatoid Arthritis

Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster I

9:00AM-11:00AM: Abstract Number: 26

Hints for Catecholamine-Driven Autocrine Mechanisms to Regulate Regulatory B Cells

B Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

9:00AM-11:00AM: Abstract Number: 44

Histone Deacetylase 1 (HDAC1): A Novel Therapeutic Target in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 297

Hospitalization Rates Among Patients with Polymyalgia Rheumatica: A Population-Based Study from 1995-2017

Health Services Research Poster I – ACR/ARHP

9:00AM-11:00AM: Abstract Number: 515

How Knowledgeable Are Patients with Rheumatoid Arthritis about Cardiovascular Disease?

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I: Comorbidities

9:00AM-11:00AM: Abstract Number: 637

How to Define Remission and Low Disease Activity in Psoriatic Arthritis? an Analysis of 419 Patients with a Double Perspective, Based on Composite Scores and Patients’ and Physicians’ Perspectives

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Imaging, Clinical Studies, and Treatment

9:00AM-11:00AM: Abstract Number: 545

How to Treat Rheumatoid Arthritis Patients When Methotrexate Has Failed? Results from the Meteor Registry

Rheumatoid Arthritis – Treatments Poster I: Strategy and Epidemiology

9:00AM-11:00AM: Abstract Number: 236

Hypogammaglobulinemia and Infection Risk in Patients Treated with Rituximab

Epidemiology and Public Health Poster I: Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].